Code Bio is a biotechnology company pioneering the development of genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its novel non-viral multivalent synthetic DNA delivery platform, 3DNA, Code Bio's approach can overcome multiple challenges inherent with viral-based delivery approaches, including immunogenicity, size and delivery limitations, inability to re-dose and manufacturing complexity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/22 | $75,000,000 | Series A |
4BIO Capital Amgen Ventures CureDuchenne Ventures Hatteras Venture Partners JDRF T1D Fund New Enterprise Associates Northpond Ventures  Takeda Ventures UCB Ventures UPMC Enterprise | undisclosed |
